Cellectis Bioresearch, Syngene Partner on Cell Line Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis bioresearch and Indian contract research organization Syngene International said today they will co-develop novel genetically customized cell lines.

The collaboration between the two companies will leverage Paris-based Cellectis bioresearch's genome customization technology and Syngene's biology platform and capabilities to develop recombinant and knock-out cell lines for oncology and ADME-Tox-based drug discovery research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.